Drugs brought to registration
According to an analysis by Pecoul et al(1), of the 1233 new drugs identified as reaching the market between 1975 and 1997, only 13 were approved for tropical diseases. Of these 13, six were developed with TDR support. Since then, additional chemical entities or drug combinations have been registered for the treatment of tropical diseases with input from TDR.
|Drug||Year of registration||Indication||Partners|
|Mefloquine||1984||Malaria||Hoffman La Roche, WRAIR|
|Halofantrine||1988||Malaria||Smith Kline Beecham, WRAIR|
|Eflornithine||1991||African trypanosomiasis||Marion Merrel Dow|
|Liposomal amphotericin B||1994||Leishmaniasis (Kala azar)||NeXstar|
|Artemether||1997||Malaria||Rhone Poulenc Rorer, Kunming|
|Artemotil (beta-arteether)||2000||Malaria||Artecef, WRAIR, Dutch Min. Dev.|
|Miltefosine||2002||Leishmaniasis (Kala azar)||Zentaris, Indian CMR|
|Chlorproguanil-dapsone||2003||Malaria||Glaxo Smith Kline, DFID|
(1) Pecoul, B. et al. (1999) Access to essential drugs in poor countries: A lost battle? Journal of the American Medical Association, 281(4): 361-367
WHAT WAS TDR ROLE?
TDR's ability to build partnerships between public and private sectors, industry, academia, and developed and developing countries, reduced the costs and risks involved in bringing new drugs for tropical diseases to registration. TDR:
- Brought partners together and provided strategic funding and technical support
- Mobilized a global network of researchers and developers capable of addressing all aspects of research and development from discovery through to registration
- Funded preclinical studies and research into discovery of new therapeutic targets
- With industry partners, orchestrated, sponsored and coordinated clinical trials in disease endemic countries following strict standards and regulatory requirements.